Superworth

Biodesix profit margin BDSX

Gross, operating and net profit as a share of revenue over the last twelve months, from 2020.

Net margin, 12 months
−27.0%
Operating margin, 12 months
−20.0%
Net margin on a year earlier
+26.7 pts
Peer median
7.3%

Over the twelve months to Jun 30, 2026, Biodesix kept −27.0% of its revenue as net profit, with an operating margin of −20.0%.

Five years earlier its net margin was −41.2%.

The median for 10 healthcare stocks of a similar size is 7.3%.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating margin
FY2025−39.8%−31.5%
FY2024−60.2%−48.4%
FY2023n/a−84.2%
FY2022n/an/a
FY2021−79.2%−75.1%
FY2020−68.8%−50.3%
FY2019n/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26−27.0%+26.7 pts−20.0%
Q1 FY26−33.3%+21.0 pts−26.0%
Q4 FY25−39.8%+20.3 pts−31.5%
Q3 FY25−49.3%+17.5 pts−40.6%
Q2 FY25−53.7%+19.4 pts−44.5%
Q1 FY25−54.3%+31.5 pts−43.8%
Q4 FY24−60.2%n/a−48.4%
Q3 FY24−66.8%n/a−53.0%
Q2 FY24−73.1%n/a−54.7%
Q1 FY24−85.8%n/a−65.6%
Q4 FY23n/an/a−84.2%
Q3 FY23n/an/an/a

Against its peers

Companies in Healthcare nearest Biodesix's size, closest first, today.

CompanyProfit margin
BDSXBiodesix−27.0%
ELMDElectromed15.3%
NATRNatures Sunshine Products3.7%
UTMDUtah Medical Products29.0%
PLXProtalix BioTherapeutics23.5%
PDEXPro DEX17.6%
INFUInfuSystem6.0%
VMDViemed Healthcare4.8%
EMBCEmbecta8.6%
ARVNArvinas2.9%
NRCNRC Health4.2%
Peer median7.3%

Where Biodesix ranks

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Biodesix

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.